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1,25(OH)2D3 administration in moderate renal failure: A prospective
double blind trial. This study represents the first randomized prospec-
tive, double-blind, placebo-controlled trial of the efficacy of
I ,25(OH),D3 on bone histology and serum biochemistry in patients with
mild to moderate renal failure. Sixteen patients with chronic renal
impairment (creatinine clearance 20 to 59 ml per mm) received either
l,25(OH)2D3, at a dose of 0.25 to 0.5 g daily (eight patients), or
placebo. Transiliac crest bone biopsies were performed before entrance
into the study and after 12 months of experimental observation. None of
the patients were symptomatic or had radiological evidence of bone
disease. Of the thirteen patients who completed the study, initial serum
1 ,25(OH)2D levels were low in seven patients and parathyroid hormone
levels were elevated in seven patients. Bone histology was abnormal in
all patients. I ,25(OH),D treatment was associated with a significant fall
in serum phosphorus and alkaline phosphatase concentrations as well
as with histological evidence of an amelioration of hyperparathyroid
changes. In contrast to previous reports, no deterioration of renal
function attributable to the treatment occurred, perhaps because a
modest dose of l,25(OH)2D3 was employed combined with meticulous
monitoring. Further investigation is required to determine whether
alternative therapeutic strategies (smaller doses or intermittent therapy)
may avoid the potential for suppressing bone turnover to abnormally
low levels in the long term.
Bone disease and the need for parathyroid surgery continue
to bedevil patients with chronic renal failure. Prevention of
bone disease and hyperparathyroidism with vitamin D metabo-
lites appears logical, but long-term placebo-controlled studies in
patients with mild to moderate renal impairment are not avail-
able. The few published prospective placebo-controlled studies
have involved patients with end-stage renal failure [1, 2].
Histological evidence of bone disease is present early in the
evolution of chronic renal failure [31 as is evidence of reduced
vitamin D effects on the target organs, bone and gut [4, 51.
Blood levels of 1 ,25(OH)2D have been reported previously to be
normal or high [6—8]. More recent reports indicate serum
l,25(OH)2D levels to be low in mild to moderate renal impair.
ment [9, 10] and to be inversely correlated with glomerular
filtration rate [11]. These values must, however, be interpreted
in the light of the biochemical derangements associated with
Received for publication February 18, 1988
and in revised form July 15, 1988
© 1989 by the International Society of Nephrology
mild to moderate renal impairment, under which circumstance
elevated serum levels of 1,25(OH)2D would be appropriate [121.
It appears logical, therefore, to substitute 1 ,25(OH)2D3 in
patients with mild to moderate renal impairment, but evidence
is scant as to whether treatment with this agent at this early
stage is of benefit. Treatment involves the risks of hypercalce-
mia, and it has been claimed [13] that an adverse effect upon
renal function may occur even in the absence of hypercalcemia.
Consequently, we have carried out a one year, double-blind
placebo-controlled trial of 1 ,25(OH)2D3 in patients with mild to
moderate renal impairment in an attempt to define whether a
beneficial effect upon serum biochemistries and histological
abnormalities can be obtained and, in particular, whether this
can be achieved without any deleterious effects upon renal
function.
Methods
Protocol
Sixteen subjects were recruited from the nephrology out-
patient clinic at St. Bartholomew's Hospital. Patients with a
creatinine clearance of 20 to 60 mI/mm were eligible for the
study. Exclusion criteria included: pregnancy, hypercalcemia,
renal stones, poorly controlled hypertension, gastrointestinal or
liver disease, urinary protein output greater than 3 g daily,
psychosis, known tetracycline allergy, treatment with medica-
tion known to affect bone (anticonvulsants, heparin, corticoste-
roids) or vitamin D metabolites in pharmacological doses within
the previous six months. Seventy-seven patients were
screened, of whom 30 met the inclusion criteria. Sixteen agreed
to take part in the study, and written informed consent was
obtained. The study was approved by the St. Bartholomew's
Hospital and Medical College Ethics Committee.
Three patients were withdrawn from the study: One, on
active treatment, had a hypersensitivity reaction to tetracycline
and was withdrawn within one week of starting the study; a
second (on placebo), suffered a myocardial infarction at 40
weeks; in the third patient (on placebo) no satisfactory bone
biopsy was obtained at 12 months. The results of these patients
are not included. Individual patient data are shown in Table 1.
Patients continued with their usual antihypertensive medica-
tion throughout the study. One patient (Pat. #15) received
thyroxine replacement and was clinically and biochemically
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Table 1. Age, sex and diagnosis of patients with moderate renal
failure receiving l,25(OH)2D3 or placebo for 12 months
Diagnosis
_________
1 58 F Uninephrectomy.
glomerulonephritis
3 64 F Membranoproliferative
glomerulonephritis
5 52 M Glomerulonephritis
6 63 M Membranous
glomerulonephritis
8 31 M Uretero-pelvicjunction obstruction
10 40 M Tubulointerstitial
disease
11 56 M Glomerulonephritis
12 36 M Glomerulonephritis
l3 61 F Cortical necrosis
14 55 F Hypertensive
nephrosclerosis
IS 63 F Hypertensive
nephropathy
16 52 M Glomerulonephritis
17 51 F Glomerulonephritis
Biochemical measurements
Serum and urine calcium, phosphorus and creatinine concen-
trations, and serum alkaline phosphatase concentration were
measured by standard autoanalyzer methods.
Parathyroid hormone was estimated using a C terminal radio-
immunoassay from Immuno Nuclear Corporation (Stillwater,
Minnesota, USA) [14]. The coefficient of variation of this
method was < 10% and normal values < 0.9 j.g/ml.
Blood levels of 1 ,25(OH)2D were measured with a modifica-
tion of the method described previously [15]. The technique
involved lipid extraction from I to 2 ml serum samples using
acetonitrile and disposable C-18 columns (Waters Associates,
Milford, Massachusetts, USA) followed by automated high-
pressure liquid chromatography (HPLC) with Silica column(Waters Associates). The HPLC fraction containing
I ,25(OH)2D was measured in duplicate by competitive binding
assay utilizing a semipurified receptor from calf thymus [161.
Intraassay variation was 5%; interassay variation was 9%.
Blood levels of 25(OH)D were measured with a competitive
binding assay that utilizes rat serum [171. Intraassay variation
was 5%; interassay variation was 10%.
euthyroid throughout the study. Oral aluminum containing
phosphate binders were required only in one patient (Pat. #11).
A renal dietician assessed all the patients before entry to the
study in order to ensure an oral calcium intake of 800 mg daily—
oral calcium supplements being taken when necessary in the
morning (Pats. #1, 3, 6, and 15). No specific instructions as to
protein and phosphorus intake were given but patients were
instructed to continue their usual diet throughout the study.
There is no evidence that any patient restricted protein intake to
a great extent after commencing the study.
The study was designed as a double-blind placebo-controlled
study lasting 12 months. Patients were allocated randomly to
receive l,25(OH)2D3 or a matching placebo. The initial dose of
1 ,25(OH)2D3 was 0.25 .tg daily. If serum calcium remained
below 2.6 mmol/liter and the urinary calcium was less than 7
mmol/24 hr, the dose was doubled between four and eight
weeks after commencement of treatment. If hypercalcemia and!
or hypercalciuria occurred the trial medication was stopped.
When serum and/or urine calcium had returned to normal,
treatment was recommended at half the previous dose. To rule
out substrate deficiencies, all patients received 400 IU of
vitamin D3. Initial assessment included: history and physical
examinations, urinalysis, and measurement of fasting total
serum calcium (Ca), phosphorus (P), creatinine (Cr), alkaline
phosphatase (AP), parathyroid hormone (PTH), 25 hydroxy-
cholecalciferol, 1,25 dihydroxycholecalciferol, and creatinine
clearance (mean of two measurements). Twenty-four hour
urinary calcium and phosphorus excretions were measured on
two occasions before commencement of the study. X-rays of
hands, feet, clavicles and skull were carried out as was an initial
bone biopsy.
Patients were seen at a minimum of four weekly intervals in
a special research clinic. At each attendance symptoms were
noted, blood pressure checked, and fasting blood drawn for all
serum and urine biOchemical parameters measured at baseline.
Radiographs were repeated at 6 and 12 months, and the iliac
crest bone biopsy repeated at 12 months.
Bone histology and histomorphometry
Patients received tetracycline hydrochloride (Acromycin) 250
mg four times daily for two days. Ten days thereafter, they
received demeclotetracycline (Declomycin®), 150 mg, four
times daily for four days. After a further interval of four days,
a transiliac crest bone biopsy was performed.
Bone samples were fixed in ethanol, dehydrated, and embed-
ded in methylmethacrylate for mineralized bone histology.
Serial undecalcified sections of 3- and 7-.tm thickness were cut
using a Reichert Jung microtome (Model 1140, Reichert Scien-
tific Co., Buffalo, New York, USA). Three-gm thick sections
were stained with the modified Masson-Goldner trichrome
stain, which permits discrimination between mineralized and
nonmineralized bone and gives excellent cellular detail [18].
Seven-pm thick unstained sections were prepared for phase
contrast and fluorescent light microscopy. In addition, 7-m
thick sections were stained with the aurin tricarboxylic acid
stain for detection of aluminum [191. Static and dynamic param-
eters of bone structure, bone formation, and resorption were
measured using the Osteoplan system (Carl Zeiss, Thornwood,
New York, USA) as previously described [201.
The following histomorphometric parameters were obtained:
(a) cancellous bone mass, that is, percentage of total bone
occupied by trabecular bone; (b) mean trabecular diameter; (c)
mean trabecular plate density, that is, cancellous bone mass X
10 per mean trabecular plate thickness; (d) mean wall thickness,
the mean distance between cement lines and the trabecular
surfaces of completed structural units; (e) lamellar osteoid
volume, the percentage of bone occupied by lamellar osteoid;
(1) woven osteoid volume, the percentage of bone occupied by
woven osteoid; (g) lamellar osteoid surface, the percentage of
trabecular surface covered by lamellar osteoid; (h) woven
osteoid surface, the percentage of trabecular surface covered
by woven osteoid; (i) mean thickness of lamellar osteoid; (j)
bone-osteoblast interface, that is, percentage of trabecular
surface covered by osteoblasts; (k) osteoblastic index, the
number of osteoblasts per 100 mm trabecular boundary length
Pt. no. Age Sex Therapy
I ,25(OH),D3
I ,25(OH)2D3
I ,25(OH)2D3
Placebo
Placebo
Placebo
I ,25(OH),D
Placebo
Placebo
Placebo
I ,25(OH)2D
I ,25(OH)2D3
I ,25(OH),D1
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(only plump cuboidal cells juxtaposed to bone and arranged in
a palisade-like manner were included in the measurement); (I)
bone-osteoclast interface, the percentage of trabecular surface
covered by mono or multinucleated osteoclasts; (m) osteoclas-
tic index, the number of osteoclasts per 100 mm trabecular
boundary length; (n) mineral apposition rate, the mean distance
between tetracycline labels x 0.73/day of labeling-free interval;
(0) double-labeled trabecular surface, the percentage of trabe-
cular surface exhibiting two distinctively separated labels; (p)
singly-labelled trabecular surface, the percentage of trabecular
surface exhibiting single labels; (q) mineralization lag time, the
mean osteoid seam thickness divided by mineralization rate; (r)
osteon remodeling time (days) per osteoclast in unit time; and
(s) stainable bone aluminum, that is, fraction of trabecular
surface exhibiting aluminum deposits at the bone-osteoid inter-
face. At least fifty optical fields were evaluated at a magnifica-
tion of x200 using an objective with 0.4 numerical aperture. All
slides were read without knowledge of biochemical results or
mode of therapy.
Statistics
Data on serum calcium, phosphorus, alkaline phosphatase,
creatinine, parathyroid hormone, 25(OH)D3, 1 ,25(OH),D, cre-
atinine clearance, urinary calcium, phosphorus and urinary
creatinine were analyzed by analysis of covariance, the initial
value being used as the covariate.
Analysis was performed using multiple regression analysis,
using the "Minitab" statistical package. Serum creatinine con-
centration was not normally distributed, so logarithmic values
of creatinine were used for analysis of covariance.
Comparison between initial and final values of histomorpho-
metric parameters of bone was made using the Wilcoxon Signed
Rank Test for non-parametric data. Comparison between ex-
perimental and normal histomorphometric data was done using
the Kruskall-Wallis analysis of variance.
Results
Compliance with treatment was excellent throughout the
study as judged by repeated direct questioning of patients. No
patient reported any adverse symptoms attributable to treat-
ment during the study. Two patients in the treatment group
tolerated l,25(OH)2D3 in the dose of 0.5 tg daily. In one patient
(Pat. #3), serum calcium reached the upper limit of normal at
the initial starting dose of 0.25 sg daily, and no increase in
dosage was made. In four patients (Pats. #11, 15, 16, and 17),
hypercalcemia occurred when the dose of I ,25(OH)2D1 was
increased to 0.5 g daily. These episodes resolved within one
week of stopping treatment, and these patients subsequently
tolerated l,25(OH)2D at 0.25 j.g daily with no further hyper-
calcemia. These episodes of hypercalcemia account for the rise
in serum calcium in the treatment as compared with the control
group, which was evident between 8 and 16 weeks (Fig. I). This
was preceded by or coincided with a rise in urinary calcium
excretion (Fig. 2), rise in serum creatinine concentration (Fig.
3), and a fall in creatinine clearance (Fig. 4) in the treatment
group. Serum calcium concentration was regularly higher in the
treatment versus the control group throughout the study. How-
ever, this difference did not achieve statistical significance
when analyzed by analysis of covariance. Urinary calcium
excretion did not differ significantly when values throughout the
Time, weeks
Fig. 1. Serum calcium during 52 weeks of administration of
l,25(OH)2D3 or placebo to patients with moderate renal failure. Sym-
bols are: (O----O) placebo; (•----•) 1,25(OH),D3.
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Fig. 3. Serum creatinine during 52 weeks of administration of
l,25(OH,D3 or placebo topatients with moderate renal failure. Sym-
bols are: (O----O) placebo; (•----•) l,25(OH),D3.
study were analyzed. There was one episode of hypercalcemia
(Pat. #14) in the placebo group.
Mean serum phosphorus rose in the placebo group, whereas,
a small fall was registered in the treatment group (Fig. 5). This
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Fig. 2. Urinary calciu,n during 52 weeks of administration of
l,25(OH),D3 or placebo to patients with moderate renal failure. Sym-
bols are: (O----O) placebo; (•----•) 1,25(OH),D3.
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Fig. 4. Creatinine clearance during 52 weeks of administration of
l,25(OH)2D3 or placebo to patients with moderate rena/failure. Sym-
bols are: (O----O) placebo; (•----•) l,25(OH),D3,
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Fig. 5. Serum phosphorus during 52 weeks of administration of
1,25(OH2D3 or placebo to patients with moderate rena/failure. Sym-
bols are: (O----O) placebo; (•----) l,25(OH)2D3.
independent effect of treatment on serum phosphorus concen-
tration was highly significant (P < 0.001) and can still be
demonstrated statistically when the patient who received an
oral phosphate binder (Pat. #11; Alucaps, 2 tabs. t.i.d.) was
excluded from the statistical analysis.
Urinary phosphorus was in the normal range in both treated
and placebo patients at the beginning of the study, and there
were no significant changes in either group during the study
(Fig. 6).
There was a significant fall (P < 0.01), albeit within the
normal range, of serum alkaline phosphatase concentration in
treatment versus control patients (Fig. 7). Moreover, serum
alkaline phosphatase levels at baseline correlated respectively
with creatinine clearance (r = —0.70; P < 0.01), and parameters
of osteoid and osteoblasts (r = 0.52 to 0.62; P < 0.05 to 0.01).
In the treated group alkaline phosphatase levels no longer
correlated with serum creatinine or creatinine clearance after
therapy; however, the correlations with parameters of osteoid
and osteoblasts were still observed (r = 0.76 to 0.62; P <
0.05). At the beginning of the study, seven of the thirteen
patients studied had elevated concentrations of parathyroid
hormone. No change in mean parathyroid hormone concentra-
I
26
24
22
20
18
16
14
75
65
0 4 8 12 16 20 24 28 32 36 40 44 48 52
Time, weeks
Fig. 6. Urinary phosphorus during 52 weeks of administration of
1,25(OH,12D3 or placebo to patients with moderate rena/failure. Sym-
bols are: (O----O) placebo; (•----•) I,25(OH)2D3.
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Fig. 7. Serum alkaline phosphatase during 52 weeks of administration
of l,25(OH2D3 or placebo to patients with moderate renal failure.
Symbols are: (O----O) placebo; (•----•) 1,25(OH)2D1.
lion occurred in the placebo group during the study. A trend
towards a fall in serum parathyroid hormone concentration was
observed in the treatment group (Table 1); however, it did not
reach statistical significance.
Mean 25-hydroxy D concentrations were in the low normal
range in treatment and control groups before commencement of
the study (Table 2). A rise of similar proportions in 25-hydroxy
D concentrations was observed in each group during the study
(P < 0.05).
The mean I ,25(OH)2D concentrations were low in each group
before commencement of the study, and no significant rise in
trough 1 ,25(OH),D concentrations (blood samples taken imme-
diately before the next morning dose) was observed. There was
a positive correlation between serum l,25(OH)2D levels at
baseline and at the end of the study (r 0.98; P < 0.001) in the
placebo group but not in the treatment group (r = 0.29).
During the course of the study there was a modest rise in
serum creatinine concentration (Fig. 3) and a fall in creatinine
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Table 2. Biochemical parameters in serum and urine of patients with moderate renal failure before and 12 months after therapy with
I ,25(OH),D3 placebo
Urinary Serum
Serum Urinary Serum phosphorus alkaline Serum Serum Creatinine
calcium calcium phosphorus mmol/24 phosphatase Serum 25(OH)D 1 ,25(OH)2D creatinine clearance
Pt. no. mmoi/liter mmol/24 hr mmoi/liter
-
hrs lU/mi PTH pg/mi ng/ml pg/mi mmol/iiter mi/mm
Month 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12
Placebo patients
6 2.39 2.31 4.1 4.4 1.04 1.11 24.9 31,1 61 61 0.5 0.4 17.0 36.0 21.2 32.0 .177 .177 46 39
8 2,54 2.44 1,2 0.8 1.03 1.04 26.1 30.4 76 69 0.4 0.4 5.1 16.2 15.6 16.7 .202 .177 53 47
10 2.50 2.57 2.5 0.7 1.39 1.81 27.0 24.4 96 86 0.9 1.0 II.! 35.0 4.4 3.2 .409 .569 27 23
12 2.55 2.46 1.2 0.8 1.06 1.05 25.4 28.8 61 72 0.5 0.6 11.4 27.2 4.8 8.7 .184 .194 56 50
13 2.47 2.47 0.6 0.8 1.14 1.30 15.6 13.3 98 108 0.8 0.7 15.8 27.7 26.4 37.9 .242 .235 30 24
14 2.41 2.47 1.3 5.5 1.05 1.10 14.1 24.0 42 57 0.9 0.5 50.5 47.0 23.6 35.0 .105 .100 56 58
Mean 2.48 2.45 1.65 2.17 1,12 1,24 22.2 25.3 72.3 75.5 0.67 0.60 18.5 31.5 16.0 22.2 .220 .242 44.7 40.2
±SD ±0.07 ±0.08 ±1.24 ±2.19 ±0.14 ±0.3 ±5.7 ±6.6 ±22.0 ±18.8 ±0.23 ±0.23 ±16.2 ±10.4±9.5 ±14.6±.l03 ±.166 ±13.1±14.3
1 ,25(OH)2D3 patients2.46 2.55 0.5 1.3 1.34 1.30 12.3 12.7 67 67 1.0 0.8 18.2 28.4 14.8 21.7 .242 .239 25 27
3 2.50 2.59 1.2 2.0 1.27 1.64 21.0 25.4 94 44 0.9 1.0 13.3 25.6 19.2 14.0 .211 .316 27 24
5 2.47 2.56 0.4 3.6 1.32 1.44 23.5 27.2 45 37 0.3 0.3 18.5 30.4 14.4 21.7 .180 .196 59 59
11 2.35 2.54 0.9 3.1 1.85 1.36 25.1 17.5 124 87 1.6 0.6 46.0 48.6 17.7 17.6 .367 .469 20 14
IS 2.50 2.43 1.6 2.6 1.27 1.23 20.6 27.3 72 66 0.9 0.7 27.8 36.5 11.8 16.6 .157 .168 41 37
16 2.46 2.48 3.2 4.5 1.06 1.00 25.6 28.2 61 57 0.4 0.4 24.0 31.4 18.0 16.3 .228 .239 45 44
17 2.52 2.55 0.8 0.7 1.68 1.61 10.7 9.8 53 38 1.0 0.6 13.0 38.6 16.0 15.6 .293 .378 26 15
Mean 2.47 2.53 1,23 2.54 1.40 1.37 19.8 21.2 73.7 56.6 0.87 0.63 23.0 34.2 16.0 17.6 .240 .286 34.7 31.4
±SD ±0.06 ±0.05 ±1.00 ±1.32 ±0.27 ±0.22 ±6.0 ±7.7 ±27.1 ±18.3 ±0.43 ±0.24 ±11.5 ±7.8±2.5 ±3.0±.071 ±.108 ±14 ±16.3
Norm <2.62 <7.5 male
<6.25 female
<1.65 13—42 110 <0.9 18—35 17—54 0.06—0.12 120
Statistical analysis using multiple regression analysis
clearance (Fig. 4) in each group, but there was no significant
difference in the trends between groups in this respect. Creat-
mine clearance at baseline was lower in the treated than the
control group. The difference was not statistically significant.
Highly significant correlations were found at commencement
of the trial between: (a) creatinine clearance and both serum
phosphorus (P < 0.01; r =
—0.70) and parathyroid hormone (P
<0.001; r =
—0.78); and (b) between parathyroid hormone and
creatinine clearance (r =
—0.78; P < 0.001), as well as serum
phosphorus (r = 0.76; P < 0.001).
X-rays
The x-rays taken at the start, at six monthly intervals, and at
the end of the study were not different and did not show
clear-cut pathologic findings.
Bone histology
Histomorphometric parameters of bone structure, bone for-
mation, resorption and bone dynamics are shown on Tables 3
through 5.
Parameters of bone structure
In all patients, cancellous bone mass, mean trabecular diam-
eter, mean trabecular plate density and mean wall thickness
were within the normal range at the beginning of the study and
after 12 months of therapy. No significant changes were ob-
served in these parameters (Table 4). At the beginning and end
of the study none of the patients exhibited stainable aluminum
at the bone osteoid interface or within bone.
Parameters of bone formation and resorption
Volume of lamellar osteoid was above the normal range at
baseline in two out of the seven patients who received
I ,25(OH)2D and in two of the controls receiving placebo (Table
3). Abnormal bone formation as evidenced by the presence of
woven osteoid was found at baseline in all biopsies. Mean
thickness of lamellar osteoid seams was not increased. The
number of osteoblasts per unit of trabecular boundary length
and the bone-osteoblast interface were elevated at baseline in
eight and nine patients, respectively; therefore, the mean values
for both of these histomorphometric parameters were signifi-
cantly higher in the patients than in age- and sex-matched
normal controls. Also, the number of osteoclasts per unit
trabecular boundary length and the bone-osteoclast interface
were elevated in nine and eleven patients, respectively, result-
ing in a significant increase in mean values of these parameters
at baseline in both the patients that received placebo and
1 ,25(OH)1D3. Four patients exhibited trabecular fibrosis at
baseline; those were the patients with the lowest creatinine
clearances.
Administration of placebo for 12 months did not change
lamellar osteoid volume and the number of osteoblasts and
osteoclasts as well as bone-osteoblast interface and bone-
osteoclast interface were unchanged and continued to be above
the normal range. Volume and surface of woven osteoid
showed a further increase.
Administration of 1,25(OH)2D3 for 12 months resulted in a
significant decrease in lamellar osteoid volume and thickness.
Woven osteold volume and surface were significantly reduced
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Table 3. Histomorphometric parameters of bone structure in patients with moderate renal failure before and 12 months af
I ,25(OH)2D1 or placebo
ter therapy with
1 ,25(OH)2D3 group Placebo group
NormalsaBefore After Before After
Cancellous bone 18.5 0.9 17.1 0.6 18.6 1.9 21.8 2.0 18.3 0.7
mass %
Mean trabecular 262 10 270 12 253 9 280 3 254 4
diameter pm
Mean trabecular 1.83 0.13 1.64 0.09 1.86 0,15 1.74 0.14 1.83 0.05
plate density
#1mm
Mean wall thickness 50.4 1.7 51.2 2.2 55.9 2.7 60.7 4.6 55.5 1.2
,im
Stainable aluminum 0 0 0 0 0
at the
bone-osteoid
interface %
a Age and sex-matched normal controls
Table 4. Histomorphometnc parameters of bone formation and resorption in patients with moderate renal failure before and
therapy with I ,25(OH)2D3 or placebo
12 months after
I ,25(OH)2D3 group Placebo group
Normals"Before After Before After
Lamellar osteoid 4.66 1.07 2.21 6.27 2.51 6.49 1.66 4.05 0.09
volume mnr/cm3
Lamellarosteoid 15.6 2.59 11.3 3,10 19.6 7.34 19.3 4.72 15.4 0.58
surface 9k
Mean osteoid seam 9.47 0.85 6.98 0•44b 9.76 0.90 10.70 1,24 9.51 0.18
thickness .un
Woven osteoid 1.95 07,b 0.76 0.60 0.58 0,l6 2.27 0.65 0
volume mm3lcm3
Woven osteoid 4,20 1.24a 2.06 l27a,C 1.56 0.39a 5,04 1.34a 0
surface %
Bone-osteoblast 6.18 0.82a 1.81 0.28lC 7.18 2.45a 8.28 l.84a 2.70 0.20
interface %
Osteoblastic index 429 58 127 l7c 444 I44 492 ll8 174 11
#1100 mm boundary
length
Bone-osteoclast 1.16 0.16" 0.72 0.26 1.64 0.35 1.47 0.35 0.73 0.05
interface %
Osteoclastic index 42 7,3a 24 7.2 54 13" 43 1O,6 17 0.91
#1100 mm boundary
length
- -
"Differences between experimental groups and controls (P < 0.05)
' Differences between patients treated with I ,25(OH)2D3 and placebo group (P < 0.05)
C Differences between baseline and 12 months of treatment or placebo within same group (P < 0.05)
"Age- and sex-matched normal controls
Table S. Dynamic histomorphometric parameters of bone in patients with moderate renal failure before and 12 months after therapy with
I ,25(OH)2D3 or placebo
I ,25(OH)2D3 group Placebo group
Before After Normals"Before After
Mineralization rate (i.unlday) 0.59 0.05 0.48 0.08 0.47 0.07 0.64 0.07 0.51 0.02
Doubly labelled trabecular surfaces % 3.01 .81 1.72 .41 2.6 1.07 5.8 1.26 3.76 0.68
Mineralization lag time days 17.7 3.70 16.4 2.43 21.8 2.18 17.5 2.49 18.9 0.78
Osteon remodelling time days 148 34 187 42 221 45 158 31 169 2.2
"Age- and sex-matched normal controls
and parameters of bone cells showed a decrease in the number and the number of osteoblasts as well as bone-osteoblast
of osteoblasts and osteoclasts, that is, the osteoblastic index interface was normal or low normal in all patients. The number
and osteoclastic index). At the end of 1 ,25(OH)2D3 therapy only of osteoclasts and bone-osteoclast interface was still above
five out of seven patients still exhibited some woven osteoid, normal in three patients.
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Dynamic parameters of bone
Mineral apposition rate was not significantly different from
normal controls at baseline or after therapy in all patients (Table
5). Fraction of trabecular surfaces exhibiting double or single
tetracycline labels was not different from normals at baseline.
There was a trend towards a decrease in labelling after 12
months of treatment with 1 ,25(OH)2D3 and a trend in the
placebo group toward an increase in tetracycline labelling. Both
trends did not achieve statistical significance.
Discussion
This is the first randomized prospective double-blind place-
bo-controlled trial in which the effects of l,25(OH),D3 upon
bone histology and serum biochemistry have been studied in
patients with mild to moderate renal impairment. Published
studies in patients with mild to moderate renal failure did not
include an evaluation of the effects of the natural course of the
progression of renal disease on bone [21, 22]. However, those
data on mostly static parameters of bone histology are not
substantially different from data reported here. The aim of the
present study was to explore the efficacy and safety of
1 ,25(OH)2D3 in such patients. Although patients were asymp-
tomatic with normal serum alkaline phosphatase concentrations
and normal bone x-rays, these studies cannot be described
strictly as a trial of prophylaxis with 1 ,25(OH)2D3 against the
development of bone disease since baseline bone histology was
abnormal. We have found evidence before treatment of an
increased number of bone resorbing and forming cells in all
patients, presence of woven osteoid in all patients, and fibrosis
in some patients—findings that can be ascribed to increased
parathyroid hormone activity on bone [18, 23]. The relationship
of increased parathyroid hormone activity on bone to the renal
impairment is documented by the statistically significant corre-
lations of these histomorphometric parameters with creatinine
clearance, serum creatinine, and serum phosphorus concentra-
tions. Our failure to observe a statistically significant decrease
in serum parathyroid hormone levels after I ,25(OH)2D3 therapy
might be related to the fact that a C-terminal assay was
employed for measurement of serum parathyroid hormone
concentrations. It is conceivable that this slight fall in creatinine
clearance was associated with a reduction in clearance of PTH
or C-terminal PTH fragments measured by the radioimmunoas-
say which could have blunted the ability of the assay to
recognize an inhibition of PTH secretion during 1 ,25(OH)2D3
administration.
The trend to a decrease in tetracycline labelling without a
change in mineral apposition rate is also attributable to the
lower bone turnover. The concomitant decrease in osteoid
seam thickness and lack of change in mineralization lag time is
evidence against any deterioration in mineralization induced by
I ,25(OH)2D3. The preferential fall in number of osteoblasts
provides in vivo support for the in vitro finding of the presence
of I ,25(OH)2D3 receptors in osteoblasts and not in osteoclasts
[24]. It is likely that with further therapy the number of
osteoclasts as well as osteoblasts would decrease. This treat-
ment-induced decrease in bone turnover is desirable only to the
degree that the elevated turnover is brought back to normal,
and low or below normal levels are not desirable. Whether
alternative modes of administration (use of smaller doses of
1 ,25(OH)D3 or intermittent therapy) may ultimately avoid this
potential for suppressing bone turnover to abnormally low
levels is at present unknown and requires investigation.
Serum 1 ,25(OH)2D concentrations were low or low normal at
the commencement of the study and 24-hour trough serum
1 ,25(OH)2D concentrations did not rise significantly on treat-
ment. This observation was not unexpected, given the previous
findings of Levine et al [25] that in normal humans serum levels
of l,25(OH)2D are increased four hours but not 24 hours after
oral administration of 0.5 jtg 1 ,25(OH)2D3. 1 ,25(OH)D3 treat-
ment was associated with significant effects upon serum alka-
line phosphatase and bone histology, reflecting increased avail-
ability of 1 ,25(OH)2D3.
Mean 25-hydroxy vitamin D3 concentrations were low nor-
mal before treatment (Table 2) and rose to high normal levels in
both placebo and 1 ,25(OH)2D3 treated patients during the
study. Dietary vitamin D intake in the United Kingdom may be
borderline or low, and to exclude the possibility that this might
influence results, both groups of patients received vitamin D3,
400 units daily throughout the study. This accounts, in all
probability, for the rise in 25(OH)D3 concentration observed.
A highly significant fall in serum alkaline phosphatase, albeit
within the normal range, occurred in the 1 ,25(OH)2D3 treated
group. This is in keeping with previous observations in hemo-
dialysis patients [2]. Siede, et al [26] found a correlation
between bone alkaline phosphatase and osteoid as well as
osteoblastic parameters in patients with mild to moderate renal
failure. The same histologic abnormalities and correlations
were found in the patients enrolled in this study. The percent-
age of total alkaline phosphatase of bone origin increased in
patients with mild to moderate renal failure.
Our initial treatment protocol called for the dose of
l,25(OH)2D3 to be increased to 0.5 g daily. This proved to be
too high a dose in most patients. As a result, a rise in urinary
calcium followed or accompanied by hypercalcemia occurred in
the earlier part of the study (Figs. 1, 2). This finding was
associated with a rise in serum creatinine and a fall in creatinine
clearance (Figs. 3, 4) and indicates that frequent monitoring of
urinary calcium might be a valuable tool in the detection of
impending hypercalcemia and prevention of loss of kidney
function. An adjustment of dosage was followed by a decline in
urinary calcium, correction of hypercalcemia and return of
serum creatinine and creatinine clearance to pre-existing levels.
Thereafter, serum calcium concentrations tended to be higher
in the treatment than in the control group, although this did not
reach statistical significance. A rising trend in serum phospho-
rus concentration occurred in the placebo group but not in the
treatment group, and the difference between trends was statis-
tically significant. This finding is in agreement with observa-
tions by Coen et al [27] who reported a fall in serum phosphorus
concentration with 1 ,25(OH)2D3 treatment. It is at variance
with those of Christiansen et al [28], who noted no change in
serum phosphorus.
Over the twelve months of the study, there was no significant
deterioration in renal function attributable to treatment. This
experience contrasts with that of Christiansen et al [13]. In their
study, patients with a GFR of <35 mI/mm were treated for six
months with either 4000 IU of vitamin D or 1,25(OH)2D3 at a
starting dose of 1 pjg/day. The majority of patients were unable
to tolerate this high dose owing to hypercalcemia. Their pa-
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tients differ from ours in having evidence of impaired calcium
homeostasis. In each, at least two of the following were
present: hypocalcemia; elevation of serum alkaline phospha-
tase; and reduced bone mineral content. One might have
expected this group of patients to be less at risk of developing
hypercalcemia in view of their "hungry bones", but we suspect
that the relatively high dose of I ,25(OH)2D3 used overcame this
tendency. Alternatively, the possibility of aluminum accumula-
tion in bone was not addressed, a possibility which could have
rendered the patients prone to develop hypercalcemia. We
found stainable aluminum in 5%of 100 unselected patients with
a GFR between 20 and 66 ml/min (mean 36 2.5 mI/mm) [29].
Christiansen et al [13] suggested that l,25(OH)2D3 as formu-
lated may itself be nephrotoxic irrespective of the presence of
hypercalcemia. We found no evidence to support this claim.
Our patients had less severe impairment in renal function
than those reported in previous studies [27, 28, 30, 31]. Since
1 ,25(OH)2D3 is metabolized by the kidney our patients may
have been exposed to lower concentrations of l,25(OH)2D3.
The dose of 1 ,25(OH)2D3 we chose was conservative, and we
believe this to be the main explanation for the fact that we
observed no deterioration in renal function attributable to
treatment.
The long term aim of 1 ,25(OH)2D3 treatment in patients with
mild to moderate renal impairment is to protect bones against
the consequences of progressive renal failure and to prevent
parathyroid gland hyperplasia (with the subsequent need for
parathyroid surgery) without affecting adversely renal function.
We have demonstrated that these aims are at least in part
realizable. Observation of much larger numbers of patients over
a much longer period of time will be required to define whether
the need for neck exploration can be reduced by I ,25(OH)2D3
administration started when renal impairment is of mild to
moderate degree. A previous study [2] provided no evidence of
a reduction in the need for surgery in patients receiving
l,25(OH)2D on regular hemodialysis. Treatment when end-
stage renal failure has been reached may be too late to reduce
the need for parathyroid surgery.
We are extremely nervous at the prospect that widespread
administration of 1 ,25(OH)2D3 to patients with mild to moder-
ate renal impairment might be undertaken without careful
follow-up and monitoring of urine and serum calcium and renal
function. In 1980, Paterson [321 described twenty-seven epi-
sodes of hypercalcemia in twenty-one patients resulting from
vitamin D poisoning. Two patients died. Failure of adequate
follow-up was an important reason for such poisoning. We
recommend that long-term 1 ,25(OH)2D3 administration in pa-
tients such as those we described should be carried out only if
frequent and meticulous follow-up can be ensured, and lower
doses than those used in end-stage renal failure are employed.
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